Satellos Bioscience Inc. (MSCL.TO)

CAD 0.66

(4.76%)

Long Term Debt Summary of Satellos Bioscience Inc.

  • Satellos Bioscience Inc.'s latest annual long term debt in 2023 was - CAD , down 0.0% from previous year.
  • Satellos Bioscience Inc.'s latest quarterly long term debt in 2024 Q1 was - CAD , down 0.0% from previous quarter.
  • Satellos Bioscience Inc. reported annual long term debt of - CAD in 2022, down 0.0% from previous year.
  • Satellos Bioscience Inc. reported annual long term debt of - CAD in 2021, down -100.0% from previous year.
  • Satellos Bioscience Inc. reported quarterly long term debt of - CAD for 2024 Q1, down 0.0% from previous quarter.
  • Satellos Bioscience Inc. reported quarterly long term debt of - CAD for 2023 FY, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Satellos Bioscience Inc. (2023 - 2019)

Historical Annual Long Term Debt of Satellos Bioscience Inc. (2023 - 2019)

Year Long Term Debt Long Term Debt Growth
2023 - CAD 0.0%
2022 - CAD 0.0%
2021 - CAD -100.0%
2020 1.09 Million CAD 0.0%
2019 - CAD 0.0%

Peer Long Term Debt Comparison of Satellos Bioscience Inc.

Name Long Term Debt Long Term Debt Difference
Appili Therapeutics Inc. 875.2 Thousand CAD 100.0%
Eupraxia Pharmaceuticals Inc. - CAD NaN%
Helix BioPharma Corp. - CAD NaN%
Microbix Biosystems Inc. 6.37 Million CAD 100.0%
Medicenna Therapeutics Corp. - CAD NaN%
Oncolytics Biotech Inc. 290 Thousand CAD 100.0%
Sernova Corp. - CAD NaN%